- Leili Safdarian
- - Department of Endocrinology and Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
- Elham Kheirollahi
 - - Department of Endocrinology and Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
- Ashraf Alyasin
- - Department of Endocrinology and Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
- Marzieh Agha Hossinei
- - Department of Endocrinology and Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
- Hodjatallah Saeidi
- - Department of Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Received: 7/5/2008 Accepted: 11/12/2008 - Publisher : Avicenna Research Institute |
| Related Articles |
|
| Other Format |
|
|
|
Abstract
Introduction: Repeated Implantation Failure (RIF) is the main cause of IVF failure. Antiphospholipid syndrome is one of the causes of RIF and heparin is its treatment of choice. It is not clear yet whether heparin could be effective in women with other autoimmune disorders or other causes of IVF failure. Since IVF is the choice procedure for various causes of infertility, its application for the treatment of repeated implantation failures is of critical importance. The purpose of this study was to identify the effects of heparin in women with repeated implantation failures.Materials and Methods: In this randomized clinical trial, 60 women, with two or more unsuccessful IVF cycles, referring to infertility clinic of Shariati Hospital were randomly selected irrespective of their clinical characteristics from 2006 to 2007. Male factors infertility, anatomic, infectious, endocrine, as well as genetic problems had been ruled out in the participants. Women in the treatment group received 5000 IU heparin subcutaneously twice daily, 14 days prior to IVF.Results: Gestational outcomes (Reaching the 30th week of gestation) between the two groups were the same. Positive -hCG tests were seen in 40% and 30% of the intervention and control groups respectively with no significant statistical differences. Amongst the participants, 23.3% and 16.7% of the intervention and control groups reached the 30th week of pregnancy, respectively with no significant statistical differences. Women with immunologic or thrombophilic factors had more positive -hCG tests than those with unexplained causes (58.3% vs. 27.8%) in the intervention group; although the difference was not statistically significant.Conclusion: It seems that administration of heparin has no effects on women with unexplained infertility or repeated IVF failures. Although women with immunologic or thrombophilic factors had more positive -hCG tests, more extensive trials are warranted in this regard.
Keywords:
Gestational, Outcome, Heparin, Immunological disorder, In Vitro fertilization, Luteal phase support, Repeated implantation failure, Thrombophilia To cite this article:References
- Speroff L. Fritz. M.A. Assisted Reproductive Techno-logies. Clinical Gynecology Endocrinology and Inferti-lity. 7th Edition. Published by Lippincott Williams & wilkins. 2005;p:1215-48.
- Fiedler K, Wurfel W. Effectivity of heparin in assisted reproduction. Eur J Med Res. 2004;9(4):207-14. [PubMed]
- Bose P, Blank S, Kadyrov M, Weissenborn U, Neulen J, Regan L, et all. Heparin and aspirin attenuate placen-tal apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol. 2005;192(1):23-30. [PubMed]
- Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol. 2008;77(1):51-6. [PubMed]
- Girardi G. Heparin treatment in pregnancy loss: Poten-tial therapeutic benefits beyond and coagulation. J Reprod Immuno. 2005;66(1):45-51. [PubMed]
- Sarig G, Bulmenfeld Z, Leiba R, Lanir N, Brenner B. Modulation systemic hemostatic parameters by enoxa-parin during of gestation in women with thrombophilia and pregnancy loss. Thromb Haemost. 2005;94(5): 980-5. [PubMed]
- Quenby S, Mountfield S, Cartwright JE, Whitley GS, Vince S. Effects of low-molecular-weight and unfrac-tionated heparin on trophoblast function. Obstet Gynecol. 2004;104(2):354-61. [PubMed]
- Di Simone N, Di Nicuolo F, Sanguinetti M. Frrazzani S, D`Alessio NC, Castellani R, et all. Low-Molecular-Weight heparin induces in vitro trophoblast invasive-ness: role of matrix metalloproteinases and tissue inhibitors. Placenta. 2007;28(4):298-304. [PubMed]
- Sher G, Feinman M, Zouves C, Kuttner G, Massarani G, Salem R, et all. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospho-lipid antibody seropositive women treated with heparin and aspirin. Hum Reprod. 1994;9(2):2278-83. [PubMed]
- Sher G, Maassarani G, Zouves C, Feinman M, Sohn S, Mastzner W, et all. The use of combined heparin/ aspirin and immunoglobulin G therapy in the treatment of in vitro fertilization patients with antithyroid anti-bodies. Am J Reprod Immunol. 1998; 39(4):223-5. [PubMed]
- Stern C, Catharyn L, Norris H, Hale L, Baker HW. A Randomized, double blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertiliza-tion implantation failure and antiphospholipid or anti-nuclear antibodies. Fertil Steril. 2003;80(2):376-83. [PubMed]
- Folkeringa N, Brouwerd L, Korteweg FJ, Veeger NJ, Erwich JJ, Holm JP, et all. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol. 2007;136(4):656-61. [PubMed]
- Gris J-C, Mercier E, Guere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M,et all. Low-molecular-weight heparin versus low- dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004;103:3695-9. [PubMed]
- Altomare I, Adler A, Aledort LM. The 5,10 methylen-tetrahydrofolate reductase C677T mutation and risk of fetal loss: a case series and review of the literature. Thromb J. 2007;17:5-17. [PubMed]
- Kutteh WH. Antibody-associated recurrent pregnancy loss: treatment with heparin and low dose aspirin is superior to low dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584-9. [PubMed]